Shares of Reckitt Benckiser Group plc (OTCMKTS:RBGLY – Get Rating) have been given an average recommendation of “Hold” by the eleven ratings firms that are currently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $8,650.00.
Several equities research analysts have issued reports on RBGLY shares. Jefferies Financial Group lowered Reckitt Benckiser Group from a “hold” rating to an “underperform” rating in a research note on Wednesday, March 23rd. Royal Bank of Canada raised Reckitt Benckiser Group from a “sector perform” rating to an “outperform” rating in a research note on Wednesday, May 18th. Exane BNP Paribas raised Reckitt Benckiser Group from an “underperform” rating to a “neutral” rating in a research note on Monday, March 14th. Barclays boosted their target price on Reckitt Benckiser Group from GBX 9,100 ($110.45) to GBX 9,300 ($112.88) in a research note on Tuesday, May 3rd. Finally, Sanford C. Bernstein lowered Reckitt Benckiser Group from a “market perform” rating to an “underperform” rating in a research note on Monday, March 14th.
Shares of RBGLY stock opened at $14.90 on Friday. The company has a quick ratio of 0.44, a current ratio of 0.62 and a debt-to-equity ratio of 0.95. The business has a 50-day moving average price of $15.74 and a two-hundred day moving average price of $16.22. Reckitt Benckiser Group has a 12-month low of $14.40 and a 12-month high of $18.78.
The firm also recently declared a dividend, which was paid on Thursday, June 16th. Investors of record on Friday, April 29th were issued a dividend of $0.2432 per share. The ex-dividend date was Thursday, April 28th. This represents a yield of 2.63%.
About Reckitt Benckiser Group (Get Rating)
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products in the United Kingdom, the United States, China, India, and internationally. The company offers acne treatment creams, facial washes, and cleansing pads; disinfection, hygiene, and first aid products; condoms, sex toys, and lubricants; heartburn and digestion solutions; and cough and chest congestion, multi-symptom, and sinus remedies for adults and children under the Clearasil, Dettol, Durex, Gaviscon, and Mucinex brands.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Should you invest $1,000 in Reckitt Benckiser Group right now?
Before you consider Reckitt Benckiser Group, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Reckitt Benckiser Group wasn’t on the list.
While Reckitt Benckiser Group currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here